| Authors: |
Munoz J; Mayo Clinic, Phoenix, AZ. Electronic address: munoz.javier@mayo.edu., Rosenthal A; Mayo Clinic, Phoenix, AZ., Ip A; Hackensack Meridian School of Medicine, John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ., Darrah JM; Cedars-Sinai Medical Center, Los Angeles, CA., Wang T; Genmab US Inc., Plainsboro, NJ., Zhang G; Genmab US Inc., Plainsboro, NJ., Mutebi A; Genmab US Inc., Plainsboro, NJ., Branchcomb T; Genmab US Inc., Plainsboro, NJ., Ding Z; Genmab US Inc., Plainsboro, NJ., Chhibber A; Genmab US Inc., Plainsboro, NJ., Navarro FR; Genmab, Copenhagen, Denmark., Risum M; Genmab, Copenhagen, Denmark., Atiya M; Genmab US Inc., Plainsboro, NJ., Brodkin S; Genmab US Inc., Plainsboro, NJ., Wang A; AbbVie, Inc., North Chicago, IL., Alshreef A; AbbVie, Inc., North Chicago, IL., Harb D; AbbVie, Inc., North Chicago, IL., Sacchi M; Genmab US Inc., Plainsboro, NJ., Hoehn D; Genmab US Inc., Plainsboro, NJ., Karimi YH; Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI. |